Lexaria Bioscience (LEXX) has released an update.
Lexaria Bioscience Corp. has expanded its patent portfolio with the addition of three new patents, enhancing its global standing with a total of 46 granted patents. The patents solidify Lexaria’s advancements in drug delivery technology, particularly for antiviral agents and epilepsy treatment, showcasing significant improvements in the delivery and effectiveness of medications using their proprietary DehydraTECH platform. These developments underscore Lexaria’s commitment to innovation and may bolster the company’s future business prospects.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
